A randomized, open-label, active-controlled, Phase II study of intravenous anetumab ravtansine (BAY 94- 9343) or vinorelbine in patients with advanced or metastatic malignant pleural mesothelioma overexpressing mesothelin and progressed on first line
|Effective start/end date||7/1/16 → 11/30/16|
- BAYER HEALTHCARE PHARMACEUTICALS
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.